아스텔라스 임상시험
-
A Trial of Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate Cancer
-
An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT i
-
Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia
-
A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia
-
A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subje
-
A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Tre
-
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBA
-
Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin P
-
A Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistan
-
A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors
-
Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothe
-
Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy
-
A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastri
-
Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC
-
Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1)
기업별 임상
화이자머크(MSD)로슈노바티스아스트라제네카존슨앤드존슨(얀센)BMS사노피GSK일라이 릴리애브비암젠바이엘베링거인겔하임노보 노디스크다케다길리어드모더나바이오엔테크리제네론버텍스바이오젠다이이찌산쿄아스텔라스에자이오츠카세르비에인사이트셀트리온삼성바이오에피스한미약품유한양행